Xtandi (enzalutamide) Disease area(s): Oncology Manufacturer(s): Astellas/Pfizer 2024 Sales (USD): $7.94 billion Why it sold so well: In 2024, Astellas Pharmas Xtandi, co-marketed with Pfizer, posted strong sales growth, with revenues reaching 703.1 billion ($4.64 billion) for the first nine months (April 1, 2024 to December 31, 2024), marking a 25.6% increase compared to the same period in the previous year
10.1016/j.clinbiochem.2010.03.009 90 LiD.KeY.ZhanR.LiuC.ZhaoM.ZengA.et al (2018)
RLS significantly impacts quality of life, particularly through sleep disruption and daytime fatigue
Q: What should I do if Im traveling without access to a refrigerator
Moreover, turmeric also reduces the release of harmful proteins and protects the gut lining
Assim, reduziria prejuzos na liberao de fosfatos de alta energia atravs do aumento da oxidao mitocondrial de cidos graxos no corao, resultando na diminuio do dano ao miocrdio 9